When can we expect Covid-19 Vaccine?

With Covid-19 affecting over 72 countries across the globe resulting in thousands of death, the whole world wants to know when there will be created COVID-19 antigens and vaccines to help infected people and those who are still unaffected. Although the scientist community and vaccine producers are working round the clock on a war scale to produce effective vaccines to treat this virus, they do accept the fact that effective and completely safe vaccines development will take about a year or so. With the situation declared to be a pandemic by the WHO and lockdowns take place in every city and country all over the world, this wait may seem to be an eternity. Most vaccines for proper and full scale development take about 5-15 years to reach the market. So producing effective vaccination to treat Covid-19 in a short span of time can be a record.

Factors for sufficient time consumption to develop vaccines

There are several reasons cited for requiring ample time to develop effective medication like Recombinant Coronavirus antigens to treat Covid-19. It is necessary to arrange a candidate vaccine which is ready to be tested. This development stage of the vaccine is termed as discovery and takes good number of years of benchtop biology. The viruses are required to be isolated and grown in the lab setting. However, with genetic sequencing and the introduction of new technology advances and protein visualizing microscopes, it has become possible to avoid this step. Determining vaccine candidate is now possible within weeks.

However, all the advancements made might not be able to speed up time consumed to monitor meticulously effectiveness of the candidate vaccines in people. A pre-requisite in the form of clinical trials to introduce the vaccine in the market can be termed to be a real bottleneck. They take place in 3 stages.

The first stage involves healthy volunteers in few dozens to analyze if the vaccine is completely safe. This will take around three months.
If adverse effects are not noticed in the healthy volunteers, then the research goes onto the second phase. Hundreds of people in this stage are provided with a Recombinant 2019 nCoV shot, ideally in the area which experiences Covid-19 outbreak. This allows the scientists to gather data about its effectiveness and how antibody production is spurred upon and eliminates the disease in the trial subjects. This process lasts for about 6-8 months.
In case, the situation is under control, the process enters the third phase, where thousands of people are recruited in the outbreak zone. Here, the experiment gets repeated. It takes about 6 to 8 months more, given no problems are faced with patient recruitment or availability of vaccine supply. Then the Food & Drug Administration needs to review the data gained prior to taking the decision whether to go ahead with approval of the Coronavirus Protein vaccine, which again might take few months to about a year.

The entire process, if calculated properly, which is starting of development of vaccines in January, the approved version for public use will be available in the market not before summer 2021. This is possible if the research goes perfectly as planned without any hiccup. It is indeed a herculean task constricting entire timeline ranging from concept to creating a product which can be distributed hassle-free within a couple of years. To know more, find out from https://www.genemedi.net/

It is just a handful of manufacturers who have vaccine candidates to be moved readily to the next stage which is human testing. A good number of companies across the globe are in the race to create the perfect vaccination to treat Covid-19 affordably. Even if they manage to come up with a product, they still will have to do the manufacturing and distribution. Question that will be asked by the general public to such companies is, will the producer have the necessary ability and resources to scale up production to meet growing demands of the huge number of population the world over. Otherwise health officials are likely to have a tough time trying to ration the vaccine due to limited supply.

How to speed it up?

The timelines in general are quite difficult to be compressed. Regulators and drug manufacturers do try to avoid coming out with subpar product which instead of helping to treat the patients, might only worsen the situation. The truth is making vaccines is high risk and cost extensive and hence, avoided by many small companies. Fortunately, there are few big companies who cater to the global market and have the necessary capacity to combat global pandemic. Their scientists are doing their very best to develop vaccinations that will be affordable and effective enough to cure infected patients. The respective governments are also doing their bit to encourage vaccine manufacturers to accept the challenge posed by the pandemic Covid-19 virus by providing financial incentives and spurs necessary to quicken the pace of vaccine development.